by | Apr 25, 2024 | Publications
Blood. 2024 Apr 24:blood.2023022823. doi: 10.1182/blood.2023022823. Online ahead of print. ABSTRACT Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma...
by | Apr 25, 2024 | Publications
JMIR Res Protoc. 2024 Apr 24;13:e49861. doi: 10.2196/49861. ABSTRACT BACKGROUND: Multiple myeloma (MM) is the second-most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency...
by | Apr 25, 2024 | Publications
Acta Haematol. 2024 Apr 24. doi: 10.1159/000539066. Online ahead of print. ABSTRACT INTRODUCTION: Some treatments are associated with cytomegalovirus (CMV) reactivation (CMVRA) in patients with multiple myeloma (MM). However, no reports exist on the association...
by | Apr 25, 2024 | Publications
J Hematol Oncol. 2024 Apr 24;17(1):23. doi: 10.1186/s13045-024-01530-z. ABSTRACT BACKGROUND: The autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory...
by | Apr 25, 2024 | Publications
Front Oncol. 2024 Apr 10;14:1394048. doi: 10.3389/fonc.2024.1394048. eCollection 2024. ABSTRACT Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five most active anti-MM drugs, so-called penta-refractory MM, have historically had...
by | Apr 25, 2024 | Publications
JAAD Case Rep. 2024 Mar 16;47:84-86. doi: 10.1016/j.jdcr.2023.12.024. eCollection 2024 May. NO ABSTRACT PMID:38659473 | PMC:PMC11039776 | DOI:10.1016/j.jdcr.2023.12.024